Viral Vectors And Plasmid DNA Manufacturing Market
VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 to 2031)
Viral Vectors And Plasmid DNA Manufacturing Market, by Product Type (Viral Vector, Plasma DNA, and Non-viral DNA Vectors), by Therapeutic Application (Cancer, Inherited Disorders, Infectious Diseases, and Others), by End Product (DNA Vaccines, Gene Therapy, Immunotherapy, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027
- Published In: 11 Mar, 2020
- Code: CMI962
- Pages: 201
- Formats: Excel and PDF
- Industry: Biotechnology
Viral vectors aids in transferring genetic material into target cells and therefore, used in various therapeutic areas. Viral vectors can be significantly used in vaccines development against pathogens such as Mycobacterium tuberculosis, Plasmodium falciparum, HIV, and various bio-threat targets such as filoviruses. Plasmid DNA (pDNA) is gaining traction for clinical research applications in genetic vaccination and gene therapy. It is becoming increasingly useful as novel biotechnology product for DNA vaccines and gene medicines. It can be directly used as a therapeutic agent and indirectly used for various applications such as a starting material for transient transfection to produce transient proteins and viral vector constructs. Furthermore, pDNA is used as a master-template product to support production of new and developing biopharmaceutical products and processes such as cell therapies.
Market Dynamics
Increasing approvals by regulatory authorities for novel gene therapies is expected to drive growth of the gene therapy segment. For instance, in September 2017, GeneOne Life Science, Inc., received approval from the South Korean Ministry of Food and Drug Safety (KMFDS) for an Investigational New Drug application for a Phase I/IIa study of its investigational vaccine, GLS-5300, against the Middle East Respiratory Syndrome coronavirus (MERSCoV). Moreover, in May 2019, AveXis Inc. received the U.S. Food and Drug Administration approval for its Zolgensma (onasemnogene abeparvovec-xioi), an adeno-associated virus vector-based gene therapy for the treatment of pinal muscular atrophy (SMA) in children less than two years old.
Key features of the study:
- This report provides in-depth analysis of the global viral vector and plasmid DNA manufacturing market and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2019–2027), considering 2018 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global viral vector and plasmid DNA manufacturing market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study include Lonza Group AG, FinVector Vision Therapies, Cobra Biologics and Pharmaceutical Services, Sigma-Aldrich Co. LLC, VGXI, Inc., VIROVEK, SIRION Biotech GmbH, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Sanofi, Cell and Gene Therapy Catapult, Brammer Bio, and MassBiologics.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
- The global viral vector and plasmid DNA manufacturing market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global viral vector and plasmid DNA manufacturing market
Detailed Segmentation:
- Global Viral Vector and Plasmid DNA Manufacturing Market, By Product Type:
- Viral Vector
- Retroviral Vectors
- Adenoviral Vectors
- Lentiviral Vectors
- Adeno-associated Viral Vectors
- Others
- Plasma DNA
- Non-viral DNA Vectors
- Viral Vector
- Global Viral Vector and Plasmid DNA Manufacturing Market, By Therapeutic Application:
- Cancer
- Inherited Disorders
- Infectious Diseases
- Others
- Global Viral Vector and Plasmid DNA Manufacturing Market, By End Product:
- DNA Vaccines
- Gene Therapy
- Immunotherapy
- Others
- Global Viral Vector and Plasmid DNA Manufacturing Market, By Region:
- North America
- By Product Type:
- Viral Vector
- Retroviral Vectors
- Adenoviral Vectors
- Lentiviral Vectors
- Adeno-associated Viral Vectors
- Others
- Plasma DNA
- Non-viral DNA Vectors
- Viral Vector
- By Therapeutic Application:
- Cancer
- Inherited Disorders
- Infectious Diseases
- Others
- By End Product:
- DNA Vaccines
- Gene Therapy
- Immunotherapy
- Others
- By Country:
- U.S.
- Canada
- By Product Type:
- Latin America
- By Product Type:
- Viral Vector
- Retroviral Vectors
- Adenoviral Vectors
- Lentiviral Vectors
- Adeno-associated Viral Vectors
- Others
- Plasma DNA
- Non-viral DNA Vectors
- Viral Vector
- By Therapeutic Application:
- Cancer
- Inherited Disorders
- Infectious Diseases
- Others
- By End Product:
- DNA Vaccines
- Gene Therapy
- Immunotherapy
- Others
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Product Type:
- Europe
- By Product Type:
- Viral Vector
- Retroviral Vectors
- Adenoviral Vectors
- Lentiviral Vectors
- Adeno-associated Viral Vectors
- Others
- Plasma DNA
- Non-viral DNA Vectors
- Viral Vector
- By Therapeutic Application:
- Cancer
- Inherited Disorders
- Infectious Diseases
- Others
- By End Product:
- DNA Vaccines
- Gene Therapy
- Immunotherapy
- Others
- By Country:
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- By Product Type:
- Asia Pacific
- By Product Type:
- Connected
- Regular Viral Vector
- Retroviral Vectors
- Adenoviral Vectors
- Lentiviral Vectors
- Adeno-associated Viral Vectors
- Others
- Plasma DNA
- Non-viral DNA Vectors
- By Therapeutic Application:
- Cancer
- Inherited Disorders
- Infectious Diseases
- Others
- By End Product:
- DNA Vaccines
- Gene Therapy
- Immunotherapy
- Others
- By Country:
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- By Product Type:
- Middle East
- By Product Type:
- Viral Vector
- Retroviral Vectors
- Adenoviral Vectors
- Lentiviral Vectors
- Adeno-associated Viral Vectors
- Others
- Plasma DNA
- Non-viral DNA Vectors
- Viral Vector
- By Therapeutic Application:
- Cancer
- Inherited Disorders
- Infectious Diseases
- Others
- By End Product:
- DNA Vaccines
- Gene Therapy
- Immunotherapy
- Others
- By Country:
- GCC
- Israel
- Rest of Middle East
- By Product Type:
- Africa
- By Product Type:
- Viral Vector
- Retroviral Vectors
- Adenoviral Vectors
- Lentiviral Vectors
- Adeno-associated Viral Vectors
- Others
- Plasma DNA
- Non-viral DNA Vectors
- Viral Vector
- By Therapeutic Application:
- Cancer
- Inherited Disorders
- Infectious Diseases
- Others
- By End Product:
- DNA Vaccines
- Gene Therapy
- Immunotherapy
- Others
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- By Product Type:
- North America
- Company Profiles
- Lonza Group AG *
- Company Overview
- Material Portfolio
- Financial Performance
- Key Highlights
- Market Strategies
- FinVector Vision Therapies
- Cobra Biologics and Pharmaceutical Services
- Sigma-Aldrich Co. LLC
- VGXI, Inc.
- VIROVEK
- SIRION Biotech GmbH
- FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
- Sanofi
- Cell and Gene Therapy Catapult
- Brammer Bio
- MassBiologics
- Lonza Group AG *
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Product Type
- Market Snippet, By Therapeutic Application
- Market Snippet, By End Product
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis of DROs
- Comparative Analysis of Different Types of Viral Systems
- Collaborations, Partnerships, And Agreements
- Pipeline Analysis
- New Product Launches
- Investment Opportunities
- Regulatory Scenario
- Strategies For Product Development And Application Pathways
- Brand Analysis
- Cell & Gene Therapy Manufacturing Capacities In Europe
- Porter’s Analysis
- Market Dynamics
Global Viral Vector and Plasmid DNA Manufacturing Market, By Product Type, 2016 – 2027, (US$ Mn)
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Viral Vector
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Retroviral Vectors
- Adenoviral Vectors
- Lentiviral Vectors
- Adeno-associated Viral Vectors
- Others
- Plasma DNA
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Non-viral DNA Vectors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Introduction
Global Viral Vector and Plasmid DNA Manufacturing Market, By Therapeutic Application, 2016 – 2027, (US$ Mn)
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Inherited Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Infectious Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Introduction
Global Viral Vector and Plasmid DNA Manufacturing Market, By End Product, 2016 – 2027, (US$ Mn)
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- DNA Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Gene Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Immunotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Introduction
Global Viral Vector and Plasmid DNA Manufacturing Market, By Region, 2016 – 2027, (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, For Regions, 2017–2027
- North America
- Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Therapeutic Application, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By End Product, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
- U.S.
- Canada
- Latin America
- Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Therapeutic Application, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By End Product, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Therapeutic Application, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By End Product, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Therapeutic Application, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By End Product, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Therapeutic Application, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By End Product, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Therapeutic Application, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By End Product, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Mn)
- South Africa
- Central Africa
- North Africa
- Introduction
Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Lonza Group AG *
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- FinVector Vision Therapies
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Cobra Biologics and Pharmaceutical Services
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Sigma-Aldrich Co. LLC
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- VGXI, Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- VIROVEK
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- SIRION Biotech GmbH
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Sanofi
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Cell and Gene Therapy Catapult
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Brammer Bio
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- MassBiologics
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Lonza Group AG *
- Analyst Views
Section
- References
- Research Methodology
- About Us and Sales Contact
*Browse 34 market data tables and 33 figures on "Viral Vector and Plasmid DNA Manufacturing Market” - Global forecast to 2027.
-
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
860519526
9001:2015
27001:2022
EXISTING CLIENTELE
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
